Enhancing the Clinical Trial Enterprise for Antibacterial Drug Development in the United States —November 18-19, 2019

Speakers and Panelists

Mark Albrecht, Ph.D.
Branch Chief
Anti-Bacterial (AB) Program
Division of CBRN Countermeasures
Biomedical Advanced Research and Development Authority (BARDA)
Office of the Assistant Secretary for Preparedness and Response (ASPR)
Department of Health and Human Services (DHHS)
Washington, DC

Lindsey Baden, MD
Deputy Editor at New England Journal of Medicine
Associate Professor of Medicine
Brigham and Women's Hospital
Harvard Medical School
Boston, MA

Helen Boucher, MD
Chief, Division of Geographic Medicine and Infectious Diseases
Director, Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR)
Director, Heart Transplant and Ventricular Assist Device Infectious Diseases Program
Professor of Medicine
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
Boston, MA

Sue Cammarata, MD
Chief Medical Officer
Melinta Therapeutics
Lincolnshire, IL

Ryan Cirz, PhD
Independent Consultant
San Mateo, CA

Sara Cosgrove, MD
Professor of Medicine
Division of Infectious Diseases, Johns Hopkins University School of Medicine
Associate Hospital Epidemiologist, Johns Hopkins Hospital
Baltimore, MD
Aaron Dane, MSc  
Director  
DaneStat Consulting Limited  
Macclesfield, United Kingdom

Dennis Dixon, PhD  
Chief, Bacteriology and Mycology Branch  
Division of Microbiology and Infectious Diseases  
National Institute of Allergy and Infectious Diseases (NIAID), NIH  
Bethesda, MD

Erin Duffy, PhD  
Chief of Research & Development  
CARB-X  
Boston University  
Boston, MD

Scott Evans, PhD  
Professor  
Department of Epidemiology and Biostatistics  
George Washington University  
Washington, D.C.

John Farley, MD, MPH  
Director (Acting)  
Office of Infectious Diseases (OID)  
OND, CDER, FDA  
Silver Spring, MD

Vance Fowler, MD  
Professor of Medicine  
Florence McAlister Professor of Medicine  
Professor in Molecular Genetics and Microbiology  
Duke University School of Medicine  
Durham, NC

Amanda Jezek  
Senior Vice President, Public Policy and Government Relations  
Infectious Diseases Society of America  
Arlington, VA
Nick Kartsonis, MD
Sr. Vice President, Infectious Diseases & Vaccines
Clinical Research
Merck Research Laboratories
Narbeth, PA

Wes Kim, PhD
Senior Officer, Innovation; Antibiotic Resistance Project
The Pew Charitable Trusts
Rockville, MD

Jane Knisely, PhD
Program Officer
NIAID, NIH
Bethesda, MD

Amy Leitman
Director of Policy and Advocacy
NTM Info and Research
Miami, FL

Roger Lewis, MD, PhD
Senior Medical Scientist
Berry Consultants, LLC
Austin, TX

David Melnick, MD
Chief Medical Officer
Spero Therapeutics
Cambridge, MA

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infectives (DAI), OID
OND, CDER, FDA
Silver Spring, MD

Kevin Outterson, JD
Professor of Law & N. Neal Pike Scholar in Health and Disability Law - Boston University
Executive Director, CARB-X
Boston, MA

Manos Perros, PhD
President and Chief Executive Officer
Entasis Therapeutics
Waltham, MA
Rienk Pypstra, MD, MBA
Vice President, Hospital Clinical Development Head,
Pfizer
New York, NY

Rebecca Reindel, MD
Medical Officer
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research (CBER), FDA
Silver Spring, MD

John Rex, MD
Chief Medical Officer & Director
F2G, Ltd
Manchester, UK

Dan Rubin, PhD
Statistician
Division of Biometrics IV, Office of Translational Sciences (OTS)
CDER, FDA
Silver Spring, MD

Cynthia Sears, MD
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Pamela Tenaerts, MD, MBA
Executive Director
Clinical Trials Transformation Initiative (CTTI)
Duke University
Durham, NC

Chibuzor Uchea, PhD
Science Officer
Drug-Resistant Infections Priority Program
Wellcome Trust
London, UK
Disclosures

Sue Cammarata is a full-time employee at Melinta Therapeutics.

Ryan Cirz is a paid consultant for Cipla.

Sara Cosgrove: 1) Consulting--member of an external infection adjudication committee for Theravance (past); 2) Consulting--member of an external infection adjudication committee for Basilea (current).

Aaron Dane has consulted for Achaogen, Allecrca, Amicrobe, Amplyx, Cidara, ContraFect, Davolterra, Destiny, F2G, Geom, GSK, Gyroscope, Kymab, Mironid, Nabriva, Pfizer, Phico, Pled, Roche, Scynexis, Spero, TenNor, Transcrip Partners, VenatoRx and Zavante.

Erin Duffy: CARB-X receives funding from the governments of the United States (BARDA, NIAID), United Kingdom (DHSC/GAMRIF), Germany (BMBF) and two charitable foundations, the Wellcome Trust and the Bill & Melinda Gates Foundation.

Scott Evans has grant funding from NIH. He has consultancies with AstraZeneca (Trial Executive Committee). He’s received funding for editorial activities from DeGruyter and publishing royalties from Taylor & Francis. He’s received travel expenses / honorariums for educational activities and meetings from the American Statistical Association, CIOMS, Huntington's Study Group, ACTTION, FDA, Osaka University, National Cerebral and Cardiovascular Center of Japan, NIH, Society for Clinical Trials, American Society for Microbiology, Clinical Trials Transformation Initiative, University of Colorado, UCLA, International Society for Biopharmaceutical Statistics, Deming Conference on Applied Statistics, Antimicrobial Resistance and Stewardship Conference, World Antimicrobial Congress, and the CRT Conference. Dr. Evans serves on DMC or advisory committees for Takeda / Millennium, Pfizer, Roche, Novartis, Achaogen, Genentech, Amgen, GSK, Teva, Zeiss, Dexcom, Claret Medical, Vir, Arrevus, Five Prime, Shire, Gilead, Spark, Nuvelution, Tracon, Chiesi, WAVE, Advantagene, Braeburn, Cardinal Health, Covance, Lipocine, Microbiotix, Stryker, Rakuten, BENEFIT, Alimmune, and the Austrian Breast & Colorectal Cancer Study Group (ABCSG)/Breast International Group (BIG) and the Alliance Foundation Trials (AFT).


-Grants received or pending: NIH, FDA, MedImmune, Cerexa/Forest/Actavis/Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Cubist/Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius; Genentech, Regeneron, Basilea
- Educational fees: Green Cross, Cubist, Cerexa, Durata, Theravance; Debiopharm

- Royalties: UpToDate

- Patent pending: Sepsis diagnostics

**Nick Kartsonis** a full-time employee of Merck Research Laboratories, a division of Merck & Co., Inc. He owns stock and stock options in Merck.

**Wes Kim** leads efforts to spur the innovation of new antibiotics for Pew’s antibiotic resistance project. His work focuses on research and policies that will help to advance antibiotic discovery and development. Before joining Pew, Wes was a management consultant in the pharmaceutical and life sciences industry, advising clients on R&D strategy and operations, with a focus on infectious diseases.

**Amy Leitman** is a full-time employee of NTM Info & Research, which is a non-profit advocacy group for patients with nontuberculous mycobacterial disease. Ms. Leitman has no financial conflicts of interest.

**Roger Lewis** is an employee of the County of Los Angeles, the David Geffen School of Medicine at UCLA, the Lundquist Institute, and Berry Consultants, LLC. Berry Consultants, LLC is a statistical consulting firm that specializes in the design, implementation, oversight, and interpretation of Bayesian adaptive clinical trials including Bayesian adaptive platform trials. Dr. Lewis also serves as a Board member for the Society for Clinical Trials and is a member of the Blood Products Advisory Committee for the FDA Center for Biologics Evaluation and Research (CBER).

**David Melnick** is a full-time employee of Spero Therapeutics and shareholder of AstraZeneca and Allergan.

**Kevin Outterson**: CARB-X receives funding from the governments of the United States (BARDA, NIAID), United Kingdom (DHSC/GAMRIF), Germany (BMBF) and two charitable foundations, the Wellcome Trust and the Bill & Melinda Gates Foundation.

**Manos Perros** is a full-time employee, Board Member and Shareholder of Entasis Therapeutics.

**Rienk Pypstra** is a full-time employee with Pfizer Inc. and shareholder of GSK, Allecra, AZ, Pfizer.

**John Rex** is Chief Medical Officer & Director, F2G, Ltd.; Operating Partner & Consultant, Advent Life Sciences; and Expert-in-Residence, Wellcome Trust; He sits on the scientific advisory boards of Bugworks Research, Inc.; Basilea Pharmaceutica; Forge Therapeutics, Inc.; Novo Holdings; and Roche Pharma Research & Early Development; He is a shareholder in AstraZeneca Pharmaceuticals; F2G, Ltd; Advent Life Sciences; Macrolide Pharmaceuticals; and Bugworks Research, Inc.; He has received consulting fees from Phico Therapeutics; ABAC
Therapeutics; Polyphor, Ltd.; Heptares Therapeutics, Ltd.; Gangagen, Ltd.; Meiji Seika Pharma; Basilea Pharmaceutica International Ltd.; Allegra Therapeutics GmbH; Forge Therapeutics, Inc.; SinSa Labs; AtoxBio; Peptilogics; F. Hoffmann-LaRoche, Ltd.; Novo Holdings; Innocoll; Vedanta; Progenity; Nosopharm SA; Roivant Sciences; and Shionogi Inc.

**Cynthia Sears**: BMS: Grant/Research Support, Research Grant.

**Pamela Tenaerts**: The views and opinions expressed in this presentation are those of the individual presenter and do not necessarily reflect the views of the Clinical Trials Transformation Initiative. Dr. Tenaerts is an Employee of Duke University. Salary support comes from pooled membership fees of the Clinical Trials Transformation Initiative and from an FDA grant.

**Chibuzor Uchea** is a full-time employee of Wellcome Trust.